These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 19628297

  • 1. Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy.
    Nikolic T, Welzen-Coppens JM, Leenen PJ, Drexhage HA, Versnel MA.
    Immunobiology; 2009; 214(9-10):791-9. PubMed ID: 19628297
    [Abstract] [Full Text] [Related]

  • 2. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy.
    Lo J, Clare-Salzler MJ.
    Autoimmun Rev; 2006 Jul; 5(6):419-23. PubMed ID: 16890897
    [Abstract] [Full Text] [Related]

  • 3. The role of interferon alpha in initiation of type I diabetes in the NOD mouse.
    Li Q, McDevitt HO.
    Clin Immunol; 2011 Jul; 140(1):3-7. PubMed ID: 21592863
    [Abstract] [Full Text] [Related]

  • 4. CD8+ T cells in type 1 diabetes.
    Tsai S, Shameli A, Santamaria P.
    Adv Immunol; 2008 Jul; 100():79-124. PubMed ID: 19111164
    [Abstract] [Full Text] [Related]

  • 5. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation.
    Montagnoli C, Perruccio K, Bozza S, Bonifazi P, Zelante T, De Luca A, Moretti S, D'Angelo C, Bistoni F, Martelli M, Aversa F, Velardi A, Romani L.
    Blood Cells Mol Dis; 2008 Jul; 40(1):55-62. PubMed ID: 17827038
    [Abstract] [Full Text] [Related]

  • 6. Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes.
    Li S, Zhang M, Xiang F, Zhao J, Jiang C, Zhu J.
    Vaccine; 2011 Oct 13; 29(44):7747-51. PubMed ID: 21827810
    [Abstract] [Full Text] [Related]

  • 7. Heightened interferon-alpha/beta response causes myeloid cell dysfunction and promotes T1D pathogenesis in NOD mice.
    Peng RH, Paek E, Xia CQ, Tennyson N, Clare-Salzler MJ.
    Ann N Y Acad Sci; 2006 Oct 13; 1079():99-102. PubMed ID: 17130537
    [Abstract] [Full Text] [Related]

  • 8. Is lack of peripheral tolerance induction a cause for diabetes in the non-obese diabetic mouse?
    Lund T, Strid J.
    Arch Immunol Ther Exp (Warsz); 2000 Oct 13; 48(5):405-16. PubMed ID: 11140468
    [Abstract] [Full Text] [Related]

  • 9. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type I diabetes.
    Lo J, Peng RH, Barker T, Xia CQ, Clare-Salzler MJ.
    Ann N Y Acad Sci; 2006 Oct 13; 1079():153-6. PubMed ID: 17130547
    [Abstract] [Full Text] [Related]

  • 10. Both central and peripheral tolerance mechanisms play roles in diabetes prevention in NOD-E transgenic mice.
    Mellanby RJ, Phillips JM, Parish NM, Cooke A.
    Autoimmunity; 2008 Aug 13; 41(5):383-94. PubMed ID: 18568644
    [Abstract] [Full Text] [Related]

  • 11. Disease-modifying immunotherapy for the management of autoimmune diabetes.
    Castro CN, Barcala Tabarrozi AE, Noguerol MA, Liberman AC, Dewey RA, Arzt E, Morelli AE, Perone MJ.
    Neuroimmunomodulation; 2010 Aug 13; 17(3):173-6. PubMed ID: 20134195
    [Abstract] [Full Text] [Related]

  • 12. Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?
    Li DS, Warnock GL, Tu HJ, Ao Z, He Z, Lu H, Dai LJ.
    Life Sci; 2009 Oct 07; 85(15-16):549-56. PubMed ID: 19747492
    [Abstract] [Full Text] [Related]

  • 13. Innate immunity in type 1 diabetes.
    Diana J, Gahzarian L, Simoni Y, Lehuen A.
    Discov Med; 2011 Jun 07; 11(61):513-20. PubMed ID: 21712017
    [Abstract] [Full Text] [Related]

  • 14. Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes.
    Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H, Santamaria P, Yang Y.
    Diabetes; 2007 Jun 07; 56(6):1686-93. PubMed ID: 17360980
    [Abstract] [Full Text] [Related]

  • 15. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus.
    Phillips BE, Giannoukakis N, Trucco M.
    Pediatr Endocrinol Rev; 2008 Jun 07; 5(4):873-9. PubMed ID: 18552749
    [Abstract] [Full Text] [Related]

  • 16. Dysrulation of T cell peripheral tolerance in type 1 diabetes.
    Tisch R, Wang B.
    Adv Immunol; 2008 Jun 07; 100():125-49. PubMed ID: 19111165
    [Abstract] [Full Text] [Related]

  • 17. The potential role of dendritic cells in the therapy of Type 1 diabetes.
    Lee CN, Lew AM, Wu L.
    Immunotherapy; 2013 Jun 07; 5(6):591-606. PubMed ID: 23725283
    [Abstract] [Full Text] [Related]

  • 18. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.
    Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss H, Flier JS, Strom TB.
    Proc Natl Acad Sci U S A; 2008 Oct 21; 105(42):16242-7. PubMed ID: 18852471
    [Abstract] [Full Text] [Related]

  • 19. New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes.
    Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ.
    Transl Res; 2010 May 21; 155(5):211-6. PubMed ID: 20403575
    [Abstract] [Full Text] [Related]

  • 20. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse.
    Saxena V, Ondr JK, Magnusen AF, Munn DH, Katz JD.
    J Immunol; 2007 Oct 15; 179(8):5041-53. PubMed ID: 17911589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.